{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:42:06Z","timestamp":1790221326305,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:00:00Z","timestamp":1772928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["3332021055"],"award-info":[{"award-number":["3332021055"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100225"],"award-info":[{"award-number":["82100225"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070192"],"award-info":[{"award-number":["82070192"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2023ZD0502400"],"award-info":[{"award-number":["2023ZD0502400"]}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2023YFC2508900"],"award-info":[{"award-number":["2023YFC2508900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2023-I2M-2-007"],"award-info":[{"award-number":["2023-I2M-2-007"]}]},{"DOI":"10.13039\/501100006606","name":"Tianjin Natural Science Foundation","doi-asserted-by":"crossref","award":["23JCZXJC00220"],"award-info":[{"award-number":["23JCZXJC00220"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"DOI":"10.1186\/s40164-026-00753-9","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T12:46:09Z","timestamp":1772973969000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of ruxolitinib for graft-versus-host disease prophylaxis in patients with aplastic anemia undergoing PBSC-only allogeneic stem cell transplantation: a prospective phase II study"],"prefix":"10.1186","volume":"15","author":[{"given":"Xiaoyu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runzhi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lining","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoling","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiming","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donglin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sizhou","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyou","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erlie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhe","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,8]]},"reference":[{"issue":"12","key":"753_CR1","first-page":"1155","volume":"30","author":"R Iftikhar","year":"2024","unstructured":"Iftikhar R, DeFilipp Z, DeZern AE, Pulsipher MA, Bejanyan N, Burroughs LM, et al. Allogeneic hematopoietic cell transplantation for the treatment of severe aplastic anemia: evidence-based guidelines from the American society for transplantation and cellular therapy. Trans Cell Ther. 2024;30(12):1155\u201370.","journal-title":"Trans Cell Ther"},{"issue":"15","key":"753_CR2","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/bloodadvances.2018021162","volume":"2","author":"GE Georges","year":"2018","unstructured":"Georges GE, Doney K, Storb R. Severe aplastic anemia: allogeneic bone marrow transplantation as first-line treatment. Blood Adv. 2018;2(15):2020\u20138.","journal-title":"Blood Adv"},{"issue":"3","key":"753_CR3","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/bjh.19236","volume":"204","author":"A Kulasekararaj","year":"2024","unstructured":"Kulasekararaj A, Cavenagh J, Dokal I, Foukaneli T, Gandhi S, Garg M, et al. Guidelines for the diagnosis and management of adult aplastic anaemia: a British society for haematology guideline. Br J Haematol. 2024;204(3):784\u2013804.","journal-title":"Br J Haematol"},{"issue":"12","key":"753_CR4","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1038\/s41409-024-02419-8","volume":"59","author":"LP Xu","year":"2024","unstructured":"Xu LP, Lu PH, Wu DP, Huang H, Jiang EL, Liu DH, et al. Hematopoietic stem cell transplantation activity in China 2022\u20132023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese blood and marrow transplantation registry group. Bone Marrow Trans. 2024;59(12):1726\u201334.","journal-title":"Bone Marrow Trans"},{"issue":"7","key":"753_CR5","first-page":"454","volume":"31","author":"XD Ma","year":"2025","unstructured":"Ma XD, Xu ZL, He Y, Cheng YF, Han TT, Zhang YY, et al. G-CSF-primed peripheral blood stem cell haploidentical transplantation could achieve satisfactory clinical outcomes for severe aplastic anemia patients. Trans Cell Ther. 2025;31(7):454.","journal-title":"Trans Cell Ther"},{"issue":"7","key":"753_CR6","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.bbmt.2010.10.029","volume":"17","author":"R Chu","year":"2011","unstructured":"Chu R, Brazauskas R, Kan F, Bashey A, Bredeson C, Camitta B, et al. Comparison of outcomes after transplantation of G-CSF-stimulated bone marrow grafts versus bone marrow or peripheral blood grafts from HLA-matched sibling donors for patients with severe aplastic anemia. Biol Blood and Marrow Trans. 2011;17(7):1018\u201324.","journal-title":"Biol Blood and Marrow Trans"},{"issue":"5","key":"753_CR7","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.bbmt.2016.01.012","volume":"22","author":"R Kumar","year":"2016","unstructured":"Kumar R, Kimura F, Ahn KW, Hu ZH, Kuwatsuka Y, Klein JP, et al. Comparing outcomes with bone marrow or peripheral blood stem cells as graft source for matched sibling transplants in severe aplastic anemia across different economic regions. Biol Blood and Marrow Trans. 2016;22(5):932\u201340.","journal-title":"Biol Blood and Marrow Trans"},{"issue":"4","key":"753_CR8","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1182\/blood-2007-03-081596","volume":"110","author":"H Schrezenmeier","year":"2007","unstructured":"Schrezenmeier H, Passweg JR, Marsh JC, Bacigalupo A, Bredeson CN, Bullorsky E, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood. 2007;110(4):1397\u2013400.","journal-title":"Blood"},{"issue":"11","key":"753_CR9","first-page":"CD010189","volume":"11","author":"S Kiene","year":"2024","unstructured":"Kiene S, Albrecht M, Theurich S, Scheid C, Skoetz N, Holtick U. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. The Cochrane Datab System Rev. 2024;11(11):CD010189.","journal-title":"The Cochrane Datab System Rev"},{"key":"753_CR10","doi-asserted-by":"publisher","first-page":"204062072091448","DOI":"10.1177\/2040620720914489","volume":"11","author":"R Abboud","year":"2020","unstructured":"Abboud R, Choi J, Ruminski P, Schroeder MA, Kim S, Abboud CN, et al. Insights into the role of the JAK\/STAT signaling pathway in graft-versus-host disease. Ther adv Hematol. 2020;11:2040620720914489.","journal-title":"Ther adv Hematol"},{"issue":"19","key":"753_CR11","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","volume":"382","author":"R Zeiser","year":"2020","unstructured":"Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, et al. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. The New Engl J Med. 2020;382(19):1800\u201310.","journal-title":"The New Engl J Med"},{"issue":"15","key":"753_CR12","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1182\/bloodadvances.2020002097","volume":"4","author":"R Zeiser","year":"2020","unstructured":"Zeiser R, Soci\u00e9 G. The development of ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. Blood Adv. 2020;4(15):3789\u201394.","journal-title":"Blood Adv"},{"issue":"3","key":"753_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2033122","volume":"385","author":"R Zeiser","year":"2021","unstructured":"Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, et al. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. The New Engl J Med. 2021;385(3):228\u201338.","journal-title":"The New Engl J Med"},{"key":"753_CR14","doi-asserted-by":"publisher","first-page":"1304065","DOI":"10.3389\/fimmu.2024.1304065","volume":"15","author":"E De Togni","year":"2024","unstructured":"De Togni E, Cole O, Abboud R. Janus kinase inhibition in the treatment and prevention of graft-versus-host disease. Front Immunol. 2024;15:1304065.","journal-title":"Front Immunol"},{"issue":"2","key":"753_CR15","first-page":"S30","volume":"31","author":"RB Salit","year":"2025","unstructured":"Salit RB, Ng K, Ratsamee N, Halpern AB, Mawad R, Ghiuzeli C, et al. Phase II single center prospective study of ruxolitinib in addition to standard graft versus host disease prophylaxis in patients with myelofibrosis demonstrates encouraging outcomes. Trans Cell Ther. 2025;31(2):S30\u20131.","journal-title":"Trans Cell Ther"},{"issue":"5","key":"753_CR16","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1182\/bloodadvances.2021005035","volume":"6","author":"H Ali","year":"2022","unstructured":"Ali H, Tsai NC, Synold T, Mokhtari S, Tsia W, Palmer J, et al. Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study. Blood Adv. 2022;6(5):1444\u201353.","journal-title":"Blood Adv"},{"issue":"7","key":"753_CR17","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/s41409-024-02266-7","volume":"59","author":"X Zhang","year":"2024","unstructured":"Zhang X, Zhao X, Chen S, Hao M, Zhang L, Gong M, et al. Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients. Bone Marrow Trans. 2024;59(7):997\u20131005.","journal-title":"Bone Marrow Trans"},{"key":"753_CR18","doi-asserted-by":"crossref","unstructured":"Incidence of aplastic anemia: the relevance of diagnostic criteria. By the International Agranulocytosis and Aplastic Anemia Study. Blood. 1987;70(6):1718\u201321.","DOI":"10.1182\/blood.V70.6.1718.1718"},{"issue":"3","key":"753_CR19","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1182\/blood.V45.3.355.355","volume":"45","author":"BM Camitta","year":"1975","unstructured":"Camitta BM, Rappeport JM, Parkman R, Nathan DG. Selection of patients for bone marrow transplantation in severe aplastic anemia. Blood. 1975;45(3):355\u201363.","journal-title":"Blood"},{"issue":"2","key":"753_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1365-2141.1988.tb02460.x","volume":"70","author":"A Bacigalupo","year":"1988","unstructured":"Bacigalupo A, Hows J, Gluckman E, Nissen C, Marsh J, Van Lint MT, et al. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA working party. Br J Haematol. 1988;70(2):177\u201382.","journal-title":"Br J Haematol"},{"issue":"8","key":"753_CR21","doi-asserted-by":"publisher","first-page":"e451","DOI":"10.1016\/S1473-3099(25)00069-6","volume":"25","author":"P Ljungman","year":"2025","unstructured":"Ljungman P, Alain S, Chemaly RF, Einsele H, Galaverna F, Hirsch HH, et al. Recommendations from the 10th European conference on infections in leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies. Lancet Infect Dis. 2025;25(8):e451\u201362.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"753_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount sinai acute GVHD international consortium. Biol Blood and Marrow Trans. 2016;22(1):4\u201310.","journal-title":"Biol Blood and Marrow Trans"},{"issue":"3","key":"753_CR23","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. The 2014 diagnosis and staging working group report. Biol Blood and Marrow Trans. 2015;21(3):389\u2013401.","journal-title":"Biol Blood and Marrow Trans"},{"issue":"26","key":"753_CR24","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1182\/blood-2009-12-258442","volume":"115","author":"ML MacMillan","year":"2010","unstructured":"MacMillan ML, DeFor TE, Weisdorf DJ. The best endpoint for acute GVHD treatment trials. Blood. 2010;115(26):5412\u20137.","journal-title":"Blood"},{"issue":"9","key":"753_CR25","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1038\/s41375-021-01294-2","volume":"35","author":"DP McLornan","year":"2021","unstructured":"McLornan DP, Hernandez-Boluda JC, Czerw T, Cross N, Joachim Deeg H, Ditschkowski M, et al. Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT chronic malignancies working party. Leukemia. 2021;35(9):2445\u201359.","journal-title":"Leukemia"},{"issue":"8","key":"753_CR26","first-page":"642","volume":"27","author":"MA Kharfan-Dabaja","year":"2021","unstructured":"Kharfan-Dabaja MA, Kumar A, Ayala E, Aljurf M, Nishihori T, Marsh R, et al. Standardizing definitions of hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the american society for transplantation and cellular therapy. Trans Cell Ther. 2021;27(8):642\u20139.","journal-title":"Trans Cell Ther"},{"issue":"2","key":"753_CR27","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","volume":"11","author":"O Penack","year":"2024","unstructured":"Penack O, Marchetti M, Aljurf M, Arat M, Bonifazi F, Duarte RF, et al. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European society for blood and marrow transplantation. Lancet Haematol. 2024;11(2):e147\u201359.","journal-title":"Lancet Haematol"},{"issue":"1","key":"753_CR28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cellimm.2011.01.008","volume":"268","author":"HH Ma","year":"2011","unstructured":"Ma HH, Ziegler J, Li C, Sepulveda A, Bedeir A, Grandis J, et al. Sequential activation of inflammatory signaling pathways during graft-versus-host disease (GVHD): early role for STAT1 and STAT3. Cell Immunol. 2011;268(1):37\u201346.","journal-title":"Cell Immunol"},{"issue":"1","key":"753_CR29","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/s41375-021-01360-9","volume":"36","author":"S Kim","year":"2022","unstructured":"Kim S, Ashami K, Lim S, Staser K, Vij K, Santhanam S, et al. Baricitinib prevents GvHD by increasing Tregs via JAK3 and treats established GvHD by promoting intestinal tissue repair via EGFR. Leukemia. 2022;36(1):292\u20135.","journal-title":"Leukemia"},{"issue":"13","key":"753_CR30","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1182\/blood.2024026497","volume":"145","author":"R Abboud","year":"2025","unstructured":"Abboud R, Schroeder MA, Rettig MP, Jayasinghe RG, Gao F, Eisele J, et al. Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation. Blood. 2025;145(13):1382\u201394.","journal-title":"Blood"},{"issue":"20","key":"753_CR31","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1182\/blood.2024028005","volume":"145","author":"Z DeFilipp","year":"2025","unstructured":"DeFilipp Z, Kim HT, Knight LW, O\u2019Connor SM, Dhaver SE, White M, et al. Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT. Blood. 2025;145(20):2312\u20136.","journal-title":"Blood"},{"issue":"10","key":"753_CR32","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1158\/1078-0432.CCR-20-4725","volume":"27","author":"J Pidala","year":"2021","unstructured":"Pidala J, Walton K, Elmariah H, Kim J, Mishra A, Bejanyan N, et al. Pacritinib combined with sirolimus and low-dose tacrolimus for GVHD prevention after allogeneic hematopoietic cell transplantation: preclinical and phase I trial results. Clin Cancer Res. 2021;27(10):2712\u201322.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"753_CR33","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1038\/s41409-021-01363-1","volume":"56","author":"J Courtois","year":"2021","unstructured":"Courtois J, Ritacco C, Dubois S, Canti L, Vandenhove B, Seidel L, et al. Itacitinib prevents xenogeneic GVHD in humanized mice. Bone Marrow Trans. 2021;56(11):2672\u201381.","journal-title":"Bone Marrow Trans"},{"issue":"1","key":"753_CR34","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-024-01612-y","volume":"17","author":"X Kong","year":"2024","unstructured":"Kong X, Xu Z, Wu Y, Tang X, Xue S, Miao M, et al. Increased Epstein-Barr virus reactivation following prophylaxis for cytomegalovirus infection after haploidentical haematopoietic stem cell transplantation. J Hematol Oncol. 2024;17(1):94.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"753_CR35","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/s41409-025-02542-0","volume":"60","author":"S Zhen","year":"2025","unstructured":"Zhen S, Liu L, Zhang X, Wang J, Sun J, Liang C, et al. Increased Epstein-Barr virus reactivation but similar incidence of post-transplant lymphoproliferative disorders due to pre-emptive rituximab therapy following allogeneic hematopoietic stem cell transplantation in the letermovir era for cytomegalovirus prophylaxis. Bone Marrow Trans. 2025;60(5):721\u20134.","journal-title":"Bone Marrow Trans"}],"container-title":["Experimental Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-026-00753-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00753-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00753-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T10:53:41Z","timestamp":1773053621000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40164-026-00753-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,8]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["753"],"URL":"https:\/\/doi.org\/10.1186\/s40164-026-00753-9","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,8]]},"assertion":[{"value":"6 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants signed written informed-consent forms The patents were participants of a larger study, the NICHE-BMT project, which is the retrospective analysis of the IHCAMS recipients of bone marrow transplantation. This project was approved by the IHCAMS Clinical Research Academic Committee, and by the IHCAMS Ethics Committee on February 7, 2021 (IIT2023011-EC-2). All procedures were in accordance with the ethical standards of the institutional and national research committee (Ethics committee of Blood Disease Hospital, Chinese Academy of Medical Sciences IIT2023011-EC-2) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The institutional review board approved all study procedures and forms.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}